DMK Pharmaceuticals (LTS:0A4X) EBIT : $-17.36 Mil (TTM As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is DMK Pharmaceuticals EBIT?

DMK Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-1.71 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-17.36 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. DMK Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 was -357.22%. DMK Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1,059.43%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. DMK Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 9,641.67%.

DMK Pharmaceuticals EBIT Historical Data

The historical data trend for DMK Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals EBIT Chart

DMK Pharmaceuticals Annual Data

Trend

Mar13

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-39.22

-27.38

-35.84

-32.07

-25.06

DMK Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-4.27	-2.26	-6.43	-6.96	-1.71

Competitive Comparison of DMK Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

DMK Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's EV-to-EBIT falls into.

DMK Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.36 Mil.

DMK Pharmaceuticals (LTS:0A4X) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

DMK Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-13.06 * ( 1 - 0% )	/	( (2.738	+	4.574)	/ 2 )
=	-13.06	/	3.656
=	-357.22 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.749	-	13.567	-	( 0.64	-	max(0, 15.007	-	3.451	+	0.64	))
=	2.738

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	8.957	-	9.973	-	( 6.664	-	max(0, 13.462	-	7.872	+	6.664	))
=	4.574

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

DMK Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-6.828	/	( ( (1.289 + max(-12.058, 0))	+	(0 + max(-12.191, 0)) )	/	2 )
=	-6.828	/	( ( 1.289	+	0 )	/	2 )
=	-6.828	/	0.6445
=	-1,059.43 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.664	+	2.128)	-	(13.567	+	0.175	+	1.108)
=	-12.058

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0.663	+	0.545)	-	(9.973	+	0	+	3.426)
=	-12.191

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

DMK Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-17.355	/	-0.180
	=	9,641.67 %

DMK Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

DMK Pharmaceuticals (LTS:0A4X) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (LTS:0A4X) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

DMK:USA

Address

11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130

Website

https://www.adamispharmaceuticals.com

DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.

DMK Pharmaceuticals (LTS:0A4X) Headlines

No Headlines